Clinical Trial

Safety of ENC-201-CED ENCRT

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-06; most recent amendment 2026-03-09.
Status change: Recruiting → Active, Not Recruiting 2026-03-09
Trial Details
NCT Number NCT06408311
Lead Sponsor Encellin
Collaborators: resCON Research
Conditions Diabetes Mellitus, Type 1
Enrollment 10 participants
Start Date 2024-05-01
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-11